201004-46-8 Usage
Description
Fmoc-Lys(palmitoyl)-OH, also known as N-(9-Fluorenylmethoxycarbonyl)-L-lysine palmitate, is a synthetic derivative of the naturally occurring amino acid L-lysine. It is characterized by the attachment of a palmitoyl group to the lysine residue and the presence of a 9-fluorenylmethoxycarbonyl (Fmoc) protecting group. Fmoc-Lys(palmitoyl)-OH is a white to off-white powder and is widely used in the synthesis of biologically active peptides and peptidomimetics.
Uses
Used in Pharmaceutical Industry:
Fmoc-Lys(palmitoyl)-OH is used as an intermediate in the synthesis of galanin analogs, which are known for their anticonvulsant activity. These analogs have potential therapeutic applications in the treatment of epilepsy and other seizure disorders.
Used in Peptide Synthesis:
Fmoc-Lys(palmitoyl)-OH is used as a building block in the solid-phase peptide synthesis (SPPS) of various bioactive peptides and peptidomimetics. The Fmoc protecting group allows for the stepwise addition of amino acids during the synthesis process, providing a convenient and efficient method for peptide assembly.
Used in Drug Delivery Systems:
Fmoc-Lys(palmitoyl)-OH can be incorporated into the design of drug delivery systems, such as liposomes or nanoparticles, to improve the solubility, stability, and bioavailability of therapeutic agents. The palmitoyl group may enhance the interaction of the delivery system with biological membranes, facilitating the transport of drugs across cellular barriers.
Used in Chemical Research:
Fmoc-Lys(palmitoyl)-OH serves as a valuable research tool for studying the structure-activity relationships of peptides and peptidomimetics. It can be used to investigate the effects of lipidation on peptide conformation, stability, and biological activity, providing insights into the design of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 201004-46-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,1,0,0 and 4 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 201004-46:
(8*2)+(7*0)+(6*1)+(5*0)+(4*0)+(3*4)+(2*4)+(1*6)=48
48 % 10 = 8
So 201004-46-8 is a valid CAS Registry Number.
201004-46-8Relevant articles and documents
Co-liposomes comprising a lipidated multivalent RGD-peptide and a cationic gemini cholesterol induce selective gene transfection in αvβ3 and αvβ5 integrin receptor-rich cancer cells
Misra, Santosh K.,Kondaiah, Paturu,Bhattacharya, Santanu,Boturyn, Didier,Dumy, Pascal
, p. 5758 - 5767 (2014/11/08)
The αvβ3 and αvβ5 integrins, transmembrane glycoprotein receptors, are over-expressed in numerous tumors and in endothelial cells that constitute tumor blood vessels. As this protein selectively binds to the Arg-Gly-Asp (RGD) sequence containing peptides, it is an attractive way to target tumors. Herein we have developed novel formulations for integrin mediated selective gene delivery. These formulations are composed of a novel palmitoylated tetrameric RGD containing scaffold (named RAFT-RGD), cationic gemini cholesterol (GL5) and a natural helper lipid 1,2-dioleoyl-l-α- glycero-3-phosphatidylethanolamine (DOPE). We have optimized a co-liposomal formulation to introduce the multivalent RGD-containing macromolecule in GL5: DOPE (GL5D) mixture to produce GL5D-RGD. We have unambiguously shown the selectivity of these formulations towards cancer cells that over express αvβ3 and αvβ5 integrins. Two reporter plasmids, pEGFP-C3 and PGL-3, were employed for the transfection experiments and it was shown that GL5D-RGD liposomes increased exclusively the transfection in αvβ3 and αvβ5-overexpressing HeLa cells. This journal is the Partner Organisations 2014.
Palmitoyl derivatives of GpMBP epitopes: T-cell response and peptidases susceptibility
Papini,Mazzanti,Nardi,Traggiai,Ballerini,Biagioli,Kalbacher,Beck,Deeg,Chelli,Ginanneschi,Massacesi,Vergelli
, p. 3504 - 3510 (2007/10/03)
We report for the first time the immunoadjuvant effects of lipoconjugation of peptide antigens in an in vitro system by using CD4+ T-cells. The lipopeptides obtained by conjugating a palmitoyl moiety at the Nα-terminal of Gln74 or at
